21:45 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Genentech begins Phase II of AC Immune's anti-Tau mAb for AD

AC Immune S.A. (NASDAQ:ACIU) said the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) started a Phase II trial of Anti Tau mAb (RO7105705) to treat prodromal-to-mild Alzheimer's disease. The trial start triggered a CHF14 million...
02:31 , Mar 4, 2017 |  BioCentury  |  Product Development

Diagnosing AD trials

A battery of expensive late-stage failures has made it obvious to Alzheimer’s disease companies that more and better diagnostics will be essential to get new disease-modifying therapies to patients. But so far, the approaches being...
23:45 , Nov 23, 2016 |  BC Extra  |  Clinical News

Lilly's solanezumab fails third Phase III Alzheimer's test

Eli Lilly and Co. (NYSE:LLY) lost nearly $9 billion in market cap on Wednesday when it said it was abandoning efforts to submit solanezumab (LY2062430) for regulatory approval to treat mild dementia in Alzheimer’s disease...
07:00 , Oct 24, 2016 |  BioCentury  |  Finance

Luck favors the prepared

A year’s worth of preparation for a U.S. IPO put Swiss biotech AC Immune S.A. (NASDAQ:ACIU) in the perfect position to thread the needle between the Brexit fallout and volatility around the U.S. elections. That...
07:00 , Jul 29, 2016 |  BC Extra  |  Clinical News

Genentech, AC Immune seek safer mAbs for CNS diseases

In a study published Thursday in Cell Reports, researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and AC Immune S.A. (Lausanne, Switzerland) developed a strategy that could make therapeutic antibodies safer for...
07:00 , Jul 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Microtubule-associated protein τ (tau; MAPT; FTDP-17)

Neurology INDICATION: Alzheimer's disease (AD) In vitro and mouse studies suggest a non-microglia-binding mAb against tau could help treat AD without triggering the toxic neuroinflammation caused by standard therapeutic antibodies. The mAb was generated by modifying an...
07:00 , Jul 28, 2016 |  BC Innovations  |  Targets & Mechanisms

Effectorless efficacy

In a finding that might solve the problem of dose-limiting side effects for using antibodies in CNS disorders, a Genentech-led team has engineered an anti-tau antibody for Alzheimer's disease that binds its target in the...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Company News

AC Immune, Genentech, Roche deal

AC Immune will receive a CHF14 million ($14.4 million) milestone payment from Roche’s Genentech unit under a 2012 deal to develop and commercialize antibodies against microtubule-associated protein tau (MAPT; tau; FTDP-17) for Alzheimer’s...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Company News

Eisai, Biogen Idec deal

The companies provided an update on their March 2014 deal to co-develop and co-promote Eisai’s Alzheimer’s disease candidates E2609 and BAN2401. Biogen disclosed that it paid Eisai $100 million up front under the...
07:00 , Mar 24, 2014 |  BioCentury  |  Strategy

Aggregating hypotheses

Eisai Co. Ltd. and Biogen Idec Inc. have teamed up in Alzheimer's disease to spread the risk across a portfolio of programs investigating several therapeutic hypotheses. The deal, announced on March 5, gives Eisai financial support...